T1	B-Protein	B-Protein	0	4	TCL1	TCL1	B-NP	NN	B-DNA	3	NMOD	B-DNA
O	O	O	5	13	oncogene	oncogene	I-NP	NN	I-DNA	3	NMOD	I-DNA
O	O	O	14	24	activation	activation	I-NP	NN	O	0	ROOT	O
O	O	O	25	27	in	in	B-PP	IN	O	3	NMOD	O
O	O	O	28	39	preleukemic	preleukemic	B-NP	JJ	B-cell_type	7	NMOD	B-cell_type
O	O	O	40	41	T	T	I-NP	NN	I-cell_type	7	NMOD	I-cell_type
O	O	O	42	47	cells	cell	I-NP	NNS	I-cell_type	4	PMOD	I-cell_type
O	O	O	48	52	from	from	B-PP	IN	O	7	NMOD	O
O	O	O	53	54	a	a	B-NP	DT	O	10	NMOD	O
O	O	O	55	59	case	case	I-NP	NN	O	8	PMOD	O
O	O	O	60	62	of	of	B-PP	IN	O	10	NMOD	O
O	O	O	63	69	ataxia	ataxia	B-NP	NN	O	14	NMOD	O
O	O	O	69	70	-	-	B-NP	HYPH	O	14	NMOD	O
O	O	O	70	84	telangiectasia	telangiectasia	I-NP	NN	O	11	PMOD	O
O	O	O	84	85	.	.	O	.	O	3	P	O

O	O	O	87	90	The	The	B-NP	DT	O	3	NMOD	O
T2	B-Protein	B-Protein	91	95	TCL1	TCL1	I-NP	NN	B-DNA	3	NMOD	B-DNA
O	O	O	96	104	oncogene	oncogene	I-NP	NN	I-DNA	10	SUB	I-DNA
O	O	O	105	107	on	on	B-PP	IN	O	3	NMOD	O
O	O	O	108	113	human	human	B-NP	JJ	B-DNA	7	NMOD	B-DNA
O	O	O	114	124	chromosome	chromosome	I-NP	NN	I-DNA	7	NMOD	I-DNA
O	O	O	125	130	14q32	14q32	I-NP	NN	I-DNA	4	PMOD	I-DNA
O	O	O	130	131	.	.	O	.	O	3	P	O
O	O	O	131	132	1	1	B-NP	CD	O	3	NMOD	O
O	O	O	133	135	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	O	136	144	involved	involve	I-VP	VBN	O	10	VC	O
O	O	O	145	147	in	in	B-PP	IN	O	11	VMOD	O
O	O	O	148	158	chromosome	chromosome	B-NP	NN	O	45	NMOD	O
O	O	O	159	173	translocations	translocation	I-NP	NNS	O	13	NMOD	O
O	O	O	174	175	[	[	O	(	O	28	DEP	O
O	O	O	175	176	t	t	B-NP	NN	B-DNA	20	NMOD	B-DNA
O	O	O	176	177	(	(	O	(	I-DNA	16	NMOD	I-DNA
O	O	O	177	179	14	14	B-NP	CD	I-DNA	16	NMOD	I-DNA
O	O	O	179	180	;	;	O	:	I-DNA	20	P	I-DNA
O	O	O	180	182	14	14	B-NP	CD	I-DNA	27	NMOD	I-DNA
O	O	O	182	183	)	)	O	)	I-DNA	20	NMOD	I-DNA
O	O	O	183	184	(	(	O	(	I-DNA	27	NMOD	I-DNA
O	O	O	184	187	q11	q11	B-NP	NN	I-DNA	25	NMOD	I-DNA
O	O	O	187	188	;	;	O	:	I-DNA	25	P	I-DNA
O	O	O	188	191	q32	q32	B-NP	NN	I-DNA	27	NMOD	I-DNA
O	O	O	191	192	.	.	O	.	I-DNA	27	P	I-DNA
O	O	O	192	193	1	1	B-NP	CD	I-DNA	28	DEP	I-DNA
O	O	O	193	194	)	)	O	)	I-DNA	14	NMOD	I-DNA
O	O	O	195	198	and	and	O	CC	O	39	NMOD	O
O	O	O	199	200	t	t	B-NP	NN	B-DNA	34	VMOD	B-DNA
O	O	O	200	201	(	(	O	(	I-DNA	30	NMOD	I-DNA
O	O	O	201	202	7	7	B-NP	CD	I-DNA	30	NMOD	I-DNA
O	O	O	202	203	;	;	O	:	I-DNA	34	P	I-DNA
O	O	O	203	205	14	14	B-NP	CD	I-DNA	39	NMOD	I-DNA
O	O	O	205	206	)	)	O	)	I-DNA	34	NMOD	I-DNA
O	O	O	206	207	(	(	O	(	I-DNA	39	NMOD	I-DNA
O	O	O	207	210	q35	q35	B-NP	NN	I-DNA	39	NMOD	I-DNA
O	O	O	210	211	;	;	O	:	I-DNA	39	P	I-DNA
O	O	O	211	214	q32	q32	B-NP	NN	I-DNA	45	NMOD	I-DNA
O	O	O	214	215	.	.	O	.	I-DNA	39	P	I-DNA
O	O	O	215	216	1	1	O	CD	I-DNA	39	NMOD	I-DNA
O	O	O	216	217	)	)	O	)	I-DNA	39	NMOD	I-DNA
O	O	O	217	218	]	]	O	)	O	39	NMOD	O
O	O	O	219	222	and	and	O	CC	O	45	NMOD	O
O	O	O	223	233	inversions	inversion	B-NP	NNS	O	12	PMOD	O
O	O	O	234	235	[	[	O	(	O	55	DEP	O
O	O	O	235	240	inv14	inv14	B-NP	NN	B-DNA	51	NMOD	B-DNA
O	O	O	240	241	(	(	O	(	I-DNA	51	NMOD	I-DNA
O	O	O	241	244	q11	q11	B-NP	NN	I-DNA	51	NMOD	I-DNA
O	O	O	244	245	;	;	O	:	I-DNA	51	P	I-DNA
O	O	O	245	248	q32	q32	B-NP	NN	I-DNA	55	DEP	I-DNA
O	O	O	248	249	.	.	O	.	I-DNA	51	P	I-DNA
O	O	O	249	250	1	1	O	CD	I-DNA	51	NMOD	I-DNA
O	O	O	250	251	)	)	O	)	I-DNA	51	NMOD	I-DNA
O	O	O	251	252	]	]	O	)	O	45	NMOD	O
O	O	O	253	257	with	with	B-PP	IN	O	45	NMOD	O
T9	B-Entity	B-Entity	258	261	TCR	TCR	B-NP	NN	B-DNA	61	NMOD	B-DNA
T9	I-Entity	I-Entity	262	267	alpha	alpha	B-NP	SYM	I-DNA	61	NMOD	I-DNA
T9	I-Entity	I-Entity	267	268	/	/	B-VP	SYM	I-DNA	61	P	I-DNA
T9	I-Entity	I-Entity	268	272	beta	beta	B-NP	SYM	I-DNA	61	NMOD	I-DNA
T9	I-Entity	I-Entity	273	277	loci	locus	B-NP	NNS	I-DNA	56	PMOD	I-DNA
O	O	O	278	280	in	in	B-PP	IN	O	61	NMOD	O
O	O	O	281	282	T	T	B-NP	NN	O	66	NMOD	O
O	O	O	282	283	-	-	B-NP	HYPH	O	66	NMOD	O
O	O	O	283	287	cell	cell	I-NP	NN	O	66	NMOD	O
O	O	O	288	297	leukemias	leukemia	I-NP	NNS	O	62	PMOD	O
O	O	O	297	298	,	,	O	,	O	66	P	O
O	O	O	299	303	such	such	B-PP	JJ	O	69	PMOD	O
O	O	O	304	306	as	as	I-PP	IN	O	66	NMOD	O
O	O	O	307	308	T	T	B-NP	NN	O	69	PMOD	O
O	O	O	308	309	-	-	B-NP	HYPH	O	70	NMOD	O
O	O	O	309	323	prolymphocytic	prolymphocytic	I-NP	JJ	O	71	PRD	O
O	O	O	324	325	(	(	I-NP	(	O	77	DEP	O
O	O	O	325	326	T	T	I-NP	NN	O	76	NMOD	O
O	O	O	326	327	-	-	I-NP	HYPH	O	76	P	O
O	O	O	327	330	PLL	PLL	I-NP	NN	O	77	DEP	O
O	O	O	330	331	)	)	O	)	O	72	AMOD	O
O	O	O	331	332	.	.	O	.	O	10	P	O

O	O	O	333	335	It	It	B-NP	PRP	O	2	SUB	O
O	O	O	336	338	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	O	339	343	also	also	I-VP	RB	O	2	VMOD	O
O	O	O	344	352	involved	involve	I-VP	VBN	O	2	VC	O
O	O	O	353	355	in	in	B-PP	IN	O	4	VMOD	O
O	O	O	356	357	T	T	B-NP	NN	O	12	NMOD	O
O	O	O	357	358	-	-	B-NP	HYPH	O	12	NMOD	O
O	O	O	359	364	acute	acute	I-NP	JJ	O	12	NMOD	O
O	O	O	365	368	and	and	I-NP	CC	O	12	NMOD	O
O	O	O	368	369	-	-	I-NP	HYPH	O	12	NMOD	O
O	O	O	370	377	chronic	chronic	I-NP	JJ	O	12	NMOD	O
O	O	O	378	387	leukemias	leukemia	I-NP	NNS	O	5	PMOD	O
O	O	O	388	395	arising	arise	B-VP	VBG	O	12	NMOD	O
O	O	O	396	398	in	in	B-PP	IN	O	13	VMOD	O
O	O	O	399	404	cases	case	B-NP	NNS	O	14	PMOD	O
O	O	O	405	407	of	of	B-PP	IN	O	15	NMOD	O
O	O	O	408	414	ataxia	ataxia	B-NP	NN	O	26	NMOD	O
O	O	O	414	415	-	-	O	HYPH	O	26	NMOD	O
O	O	O	415	429	telangiectasia	telangiectasia	B-NP	NN	O	26	NMOD	O
O	O	O	430	431	(	(	O	(	O	22	DEP	O
O	O	O	431	433	AT	AT	B-NP	NN	O	22	DEP	O
O	O	O	433	434	)	)	O	)	O	19	NMOD	O
O	O	O	434	435	,	,	O	,	O	26	P	O
O	O	O	436	438	an	an	B-NP	DT	O	26	NMOD	O
O	O	O	439	455	immunodeficiency	immunodeficiency	I-NP	NN	O	26	NMOD	O
O	O	O	456	464	syndrome	syndrome	I-NP	NN	O	16	PMOD	O
O	O	O	464	465	.	.	O	.	O	2	P	O

O	O	O	466	473	Similar	Similar	B-NP	JJ	O	3	NMOD	O
O	O	O	474	485	chromosomal	chromosomal	I-NP	JJ	O	3	NMOD	O
O	O	O	486	500	rearrangements	rearrangement	I-NP	NNS	O	4	SUB	O
O	O	O	501	506	occur	occur	B-VP	VBP	O	0	ROOT	O
O	O	O	507	511	also	also	B-ADVP	RB	O	4	VMOD	O
O	O	O	512	514	in	in	B-PP	IN	O	4	VMOD	O
O	O	O	515	518	the	the	B-NP	DT	O	11	NMOD	O
O	O	O	519	527	clonally	clonally	I-NP	RB	O	9	AMOD	O
O	O	O	528	536	expanded	expand	I-NP	VBN	O	11	NMOD	O
O	O	O	537	538	T	T	I-NP	NN	B-cell_type	11	NMOD	B-cell_type
O	O	O	539	544	cells	cell	I-NP	NNS	I-cell_type	6	PMOD	I-cell_type
O	O	O	545	547	in	in	B-PP	IN	O	11	NMOD	O
O	O	O	548	550	AT	AT	B-NP	NN	O	14	NMOD	O
O	O	O	551	559	patients	patient	I-NP	NNS	O	12	PMOD	O
O	O	O	560	566	before	before	B-PP	IN	O	14	NMOD	O
O	O	O	567	570	the	the	B-NP	DT	O	17	NMOD	O
O	O	O	571	581	appearance	appearance	I-NP	NN	O	15	PMOD	O
O	O	O	582	584	of	of	B-PP	IN	O	17	NMOD	O
O	O	O	585	588	the	the	B-NP	DT	O	21	NMOD	O
O	O	O	589	594	overt	overt	I-NP	JJ	O	21	NMOD	O
O	O	O	595	603	leukemia	leukemia	I-NP	NN	O	18	PMOD	O
O	O	O	603	604	.	.	O	.	O	4	P	O

O	O	O	605	607	We	We	B-NP	PRP	O	2	SUB	O
O	O	O	608	612	have	have	B-VP	VBP	O	0	ROOT	O
O	O	O	613	621	analyzed	analyze	I-VP	VBN	O	2	VC	O
O	O	O	622	625	the	the	B-NP	DT	O	5	NMOD	O
O	O	O	626	636	expression	expression	I-NP	NN	O	3	OBJ	O
O	O	O	637	639	of	of	B-PP	IN	O	5	NMOD	O
T3	B-Protein	B-Protein	640	644	TCL1	TCL1	B-NP	NN	B-RNA	8	NMOD	B-RNA
O	O	O	645	649	mRNA	mRNA	I-NP	NN	I-RNA	10	NMOD	I-RNA
O	O	O	650	653	and	and	I-NP	CC	O	10	NMOD	O
O	O	O	654	661	protein	protein	I-NP	NN	O	6	PMOD	O
O	O	O	662	664	in	in	B-PP	IN	O	10	NMOD	O
O	O	O	665	675	peripheral	peripheral	B-NP	JJ	B-cell_type	14	NMOD	B-cell_type
O	O	O	676	681	blood	blood	I-NP	NN	I-cell_type	14	NMOD	I-cell_type
O	O	O	682	693	lymphocytes	lymphocyte	I-NP	NNS	I-cell_type	11	PMOD	I-cell_type
O	O	O	694	695	(	(	O	(	O	17	DEP	O
O	O	O	695	699	PBLs	PBL	B-NP	NNS	B-cell_type	17	DEP	B-cell_type
O	O	O	699	700	)	)	O	)	O	14	NMOD	O
O	O	O	701	705	from	from	B-PP	IN	O	14	NMOD	O
O	O	O	706	710	four	four	B-NP	CD	O	21	NMOD	O
O	O	O	711	713	AT	AT	I-NP	NN	O	21	NMOD	O
O	O	O	714	719	cases	case	I-NP	NNS	O	18	PMOD	O
O	O	O	720	723	and	and	B-PP	CC	O	18	PMOD	O
O	O	O	724	728	from	from	B-PP	IN	O	18	PMOD	O
O	O	O	729	736	healthy	healthy	B-NP	JJ	O	25	NMOD	O
O	O	O	737	745	controls	control	I-NP	NNS	O	23	PMOD	O
O	O	O	745	746	.	.	O	.	O	2	P	O

O	O	O	747	749	We	We	B-NP	PRP	O	2	SUB	O
O	O	O	750	755	found	find	B-VP	VBD	O	0	ROOT	O
O	O	O	756	760	that	that	B-SBAR	IN	O	2	VMOD	O
O	O	O	761	764	the	the	B-NP	DT	O	6	NMOD	O
T4	B-Protein	B-Protein	765	769	TCL1	TCL1	I-NP	NN	B-DNA	6	NMOD	B-DNA
O	O	O	770	774	gene	gene	I-NP	NN	I-DNA	7	SUB	I-DNA
O	O	O	775	778	was	be	B-VP	VBD	O	3	SBAR	O
O	O	O	779	792	overexpressed	overexpresse	I-VP	VBN	O	7	VC	O
O	O	O	793	795	in	in	B-PP	IN	O	8	VMOD	O
O	O	O	796	799	the	the	B-NP	DT	O	11	NMOD	O
O	O	O	800	804	PBLs	PBL	I-NP	NNS	B-cell_type	9	PMOD	B-cell_type
O	O	O	805	807	of	of	B-PP	IN	O	11	NMOD	O
O	O	O	808	810	an	an	B-NP	DT	O	15	NMOD	O
O	O	O	811	813	AT	AT	I-NP	NN	O	15	NMOD	O
O	O	O	814	821	patient	patient	I-NP	NN	O	12	PMOD	O
O	O	O	822	826	with	with	B-PP	IN	O	15	NMOD	O
O	O	O	827	828	a	a	B-NP	DT	O	23	NMOD	O
O	O	O	829	834	large	large	I-NP	JJ	B-cell_line	23	NMOD	B-cell_line
O	O	O	835	841	clonal	clonal	I-NP	JJ	I-cell_line	23	NMOD	I-cell_line
O	O	O	842	843	T	T	I-NP	NN	I-cell_line	23	NMOD	I-cell_line
O	O	O	843	844	-	-	B-NP	HYPH	I-cell_line	23	NMOD	I-cell_line
O	O	O	844	848	cell	cell	I-NP	NN	I-cell_line	23	NMOD	I-cell_line
O	O	O	849	859	population	population	I-NP	NN	I-cell_line	16	PMOD	I-cell_line
O	O	O	860	870	exhibiting	exhibit	B-VP	VBG	O	23	NMOD	O
O	O	O	871	874	the	the	B-NP	DT	O	32	NMOD	O
O	O	O	875	876	t	t	I-NP	NN	B-DNA	32	NMOD	B-DNA
O	O	O	876	877	(	(	O	(	I-DNA	31	DEP	I-DNA
O	O	O	877	879	14	14	B-NP	CD	I-DNA	30	NMOD	I-DNA
O	O	O	879	880	;	;	O	:	I-DNA	30	P	I-DNA
O	O	O	880	882	14	14	B-NP	CD	I-DNA	31	DEP	I-DNA
O	O	O	882	883	)	)	O	)	I-DNA	26	NMOD	I-DNA
O	O	O	884	897	translocation	translocation	B-NP	NN	I-DNA	24	OBJ	I-DNA
O	O	O	898	901	but	but	B-PP	CC	O	9	PMOD	O
O	O	O	902	905	not	not	B-PP	RB	O	35	PMOD	O
O	O	O	906	908	in	in	I-PP	IN	O	9	PMOD	O
O	O	O	909	912	the	the	B-NP	DT	O	37	NMOD	O
O	O	O	913	924	lymphocytes	lymphocyte	I-NP	NNS	B-cell_type	35	PMOD	B-cell_type
O	O	O	925	927	of	of	B-PP	IN	O	37	NMOD	O
O	O	O	928	931	the	the	B-NP	DT	O	41	NMOD	O
O	O	O	932	937	other	other	I-NP	JJ	O	41	NMOD	O
O	O	O	938	943	cases	case	I-NP	NNS	O	38	PMOD	O
O	O	O	943	944	.	.	O	.	O	2	P	O

O	O	O	945	957	Fluorescence	Fluorescence	B-NP	NN	O	4	NMOD	O
O	O	O	958	960	in	in	B-NP	FW	O	3	AMOD	O
O	O	O	961	965	situ	situ	I-NP	FW	O	4	NMOD	O
O	O	O	966	979	hybridization	hybridization	I-NP	NN	O	24	SUB	O
O	O	O	980	982	of	of	B-PP	IN	O	4	NMOD	O
O	O	O	983	986	the	the	B-NP	DT	O	9	NMOD	O
T5	B-Protein	B-Protein	987	991	TCL1	TCL1	I-NP	NN	B-DNA	9	NMOD	B-DNA
T10	B-Entity	B-Entity	992	999	genomic	genomic	I-NP	JJ	I-DNA	9	NMOD	I-DNA
T10	I-Entity	I-Entity	1000	1005	locus	locus	I-NP	NN	I-DNA	5	PMOD	I-DNA
O	O	O	1006	1008	to	to	B-PP	TO	O	4	NMOD	O
O	O	O	1009	1019	lymphocyte	lymphocyte	B-NP	NN	O	12	NMOD	O
O	O	O	1020	1030	metaphases	metaphase	I-NP	NNS	O	10	PMOD	O
O	O	O	1031	1035	from	from	B-PP	IN	O	12	NMOD	O
O	O	O	1036	1039	the	the	B-NP	DT	O	16	NMOD	O
O	O	O	1040	1042	AT	AT	I-NP	NN	O	16	NMOD	O
O	O	O	1043	1050	patient	patient	I-NP	NN	O	13	PMOD	O
O	O	O	1051	1055	with	with	B-PP	IN	O	16	NMOD	O
O	O	O	1056	1059	the	the	B-NP	DT	O	23	NMOD	O
O	O	O	1060	1061	T	T	I-NP	NN	O	23	NMOD	O
O	O	O	1061	1062	-	-	I-NP	HYPH	O	23	NMOD	O
O	O	O	1062	1066	cell	cell	I-NP	NN	O	23	NMOD	O
O	O	O	1067	1073	clonal	clonal	I-NP	JJ	O	23	NMOD	O
O	O	O	1074	1083	expansion	expansion	I-NP	NN	O	17	PMOD	O
O	O	O	1084	1090	showed	show	B-VP	VBD	O	0	ROOT	O
O	O	O	1091	1095	that	that	B-SBAR	IN	O	24	VMOD	O
O	O	O	1096	1099	the	the	B-NP	DT	O	27	NMOD	O
O	O	O	1100	1110	breakpoint	breakpoint	I-NP	NN	O	37	SUB	O
O	O	O	1111	1113	of	of	B-PP	IN	O	27	NMOD	O
O	O	O	1114	1117	the	the	B-NP	DT	O	36	NMOD	O
O	O	O	1118	1119	t	t	I-NP	NN	B-DNA	36	NMOD	B-DNA
O	O	O	1119	1120	(	(	O	(	I-DNA	35	DEP	I-DNA
O	O	O	1120	1122	14	14	B-NP	CD	I-DNA	34	NMOD	I-DNA
O	O	O	1122	1123	;	;	O	:	I-DNA	34	P	I-DNA
O	O	O	1123	1125	14	14	B-NP	CD	I-DNA	35	DEP	I-DNA
O	O	O	1125	1126	)	)	O	)	I-DNA	30	NMOD	I-DNA
O	O	O	1127	1140	translocation	translocation	B-NP	NN	I-DNA	28	PMOD	I-DNA
O	O	O	1141	1145	lies	lie	B-VP	VBZ	O	25	SBAR	O
O	O	O	1146	1152	within	within	B-PP	IN	O	37	VMOD	O
O	O	O	1153	1156	the	the	B-NP	DT	O	41	NMOD	O
T6	B-Protein	B-Protein	1157	1161	TCL1	TCL1	I-NP	NN	B-DNA	41	NMOD	B-DNA
T11	B-Entity	B-Entity	1162	1167	locus	locus	I-NP	NN	I-DNA	38	PMOD	I-DNA
O	O	O	1168	1171	and	and	O	CC	O	37	VMOD	O
O	O	O	1172	1174	is	be	B-VP	VBZ	O	37	VMOD	O
O	O	O	1175	1186	accompanied	accompany	I-VP	VBN	O	43	VC	O
O	O	O	1187	1189	by	by	B-PP	IN	O	44	VMOD	O
O	O	O	1190	1192	an	an	B-NP	DT	O	48	NMOD	O
O	O	O	1193	1201	inverted	invert	I-NP	VBN	O	48	NMOD	O
O	O	O	1202	1213	duplication	duplication	I-NP	NN	O	45	PMOD	O
O	O	O	1214	1216	of	of	B-PP	IN	O	48	NMOD	O
O	O	O	1217	1220	the	the	B-NP	DT	O	52	NMOD	O
T12,T13	B-Entity,B-Entity	B-Entity,B-Entity	1221	1227	distal	distal	I-NP	JJ	B-DNA	52	NMOD	B-DNA
T12,T13	I-Entity,I-Entity	I-Entity,I-Entity	1228	1232	part	part	I-NP	NN	I-DNA	49	PMOD	I-DNA
T12	I-Entity	I-Entity	1233	1235	of	of	B-PP	IN	O	52	NMOD	O
T12	I-Entity	I-Entity	1236	1246	chromosome	chromosome	B-NP	NN	B-DNA	53	PMOD	B-DNA
T12	I-Entity	I-Entity	1247	1249	14	14	I-NP	CD	I-DNA	54	NMOD	I-DNA
O	O	O	1249	1250	.	.	O	.	O	24	P	O

O	O	O	1251	1256	These	These	B-NP	DT	O	2	NMOD	O
O	O	O	1257	1261	data	datum	I-NP	NNS	O	3	SUB	O
O	O	O	1262	1270	indicate	indicate	B-VP	VBP	O	0	ROOT	O
O	O	O	1271	1275	that	that	B-SBAR	IN	O	3	VMOD	O
T7	B-Protein	B-Protein	1276	1280	TCL1	TCL1	B-NP	NN	B-protein	6	SUB	B-protein
O	O	O	1281	1283	is	be	B-VP	VBZ	O	4	SBAR	O
O	O	O	1284	1293	activated	activate	I-VP	VBN	O	6	VC	O
O	O	O	1294	1296	in	in	B-PP	IN	O	7	VMOD	O
O	O	O	1297	1308	preleukemic	preleukemic	B-NP	JJ	B-cell_line	11	NMOD	B-cell_line
O	O	O	1309	1315	clonal	clonal	I-NP	JJ	I-cell_line	11	NMOD	I-cell_line
O	O	O	1316	1321	cells	cell	I-NP	NNS	I-cell_line	8	PMOD	I-cell_line
O	O	O	1322	1324	as	as	B-PP	IN	O	7	VMOD	O
O	O	O	1325	1326	a	a	B-NP	DT	O	14	NMOD	O
O	O	O	1327	1338	consequence	consequence	I-NP	NN	O	12	PMOD	O
O	O	O	1339	1341	of	of	B-PP	IN	O	14	NMOD	O
O	O	O	1342	1352	chromosome	chromosome	B-NP	NN	B-DNA	17	NMOD	B-DNA
O	O	O	1353	1366	translocation	translocation	I-NP	NN	I-DNA	15	PMOD	I-DNA
O	O	O	1367	1376	involving	involve	B-VP	VBG	I-DNA	17	NMOD	I-DNA
T14	B-Entity	B-Entity	1377	1386	sequences	sequence	B-NP	NNS	I-DNA	18	OBJ	I-DNA
T14	I-Entity	I-Entity	1387	1391	from	from	B-PP	IN	O	19	NMOD	O
T14	I-Entity	I-Entity	1392	1395	the	the	B-NP	DT	O	23	NMOD	O
T14,T15	I-Entity,B-Entity	I-Entity,B-Entity	1396	1399	TCR	TCR	I-NP	NN	B-DNA	23	NMOD	B-DNA
T14,T15	I-Entity,I-Entity	I-Entity,I-Entity	1400	1405	locus	locus	I-NP	NN	I-DNA	20	PMOD	I-DNA
T14	I-Entity	I-Entity	1406	1408	at	at	B-PP	IN	O	23	NMOD	O
T14,T16	I-Entity,B-Entity	I-Entity,B-Entity	1409	1414	14q11	14q11	B-NP	NN	B-DNA	24	PMOD	B-DNA
O	O	O	1414	1415	.	.	O	.	O	3	P	O

O	O	O	1416	1428	Deregulation	Deregulation	B-NP	NN	O	4	SUB	O
O	O	O	1429	1431	of	of	B-PP	IN	O	1	NMOD	O
T8	B-Protein	B-Protein	1432	1436	TCL1	TCL1	B-NP	NN	B-protein	2	PMOD	B-protein
O	O	O	1437	1439	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	O	1440	1443	the	the	B-NP	DT	O	7	NMOD	O
O	O	O	1444	1449	first	first	I-NP	JJ	O	7	NMOD	O
O	O	O	1450	1455	event	event	I-NP	NN	O	4	PRD	O
O	O	O	1456	1458	in	in	B-PP	IN	O	7	NMOD	O
O	O	O	1459	1462	the	the	B-NP	DT	O	10	NMOD	O
O	O	O	1463	1473	initiation	initiation	I-NP	NN	O	8	PMOD	O
O	O	O	1474	1476	of	of	B-PP	IN	O	10	NMOD	O
O	O	O	1477	1487	malignancy	malignancy	B-NP	NN	O	11	PMOD	O
O	O	O	1488	1490	in	in	B-PP	IN	O	10	NMOD	O
O	O	O	1491	1496	these	these	B-NP	DT	O	15	NMOD	O
O	O	O	1497	1502	types	type	I-NP	NNS	O	13	PMOD	O
O	O	O	1503	1505	of	of	B-PP	IN	O	15	NMOD	O
O	O	O	1506	1515	leukemias	leukemia	B-NP	NNS	O	16	PMOD	O
O	O	O	1516	1519	and	and	O	CC	O	4	VMOD	O
O	O	O	1520	1530	represents	represent	B-VP	VBZ	O	4	VMOD	O
O	O	O	1531	1532	a	a	B-NP	DT	O	22	NMOD	O
O	O	O	1533	1542	potential	potential	I-NP	JJ	O	22	NMOD	O
O	O	O	1543	1547	tool	tool	I-NP	NN	O	19	OBJ	O
O	O	O	1548	1551	for	for	B-PP	IN	O	22	NMOD	O
O	O	O	1552	1560	clinical	clinical	B-NP	JJ	O	25	NMOD	O
O	O	O	1561	1571	evaluation	evaluation	I-NP	NN	O	23	PMOD	O
O	O	O	1571	1572	.	.	O	.	O	4	P	O
